New Therapeutic Option Shows Promise for Pancreatic Cancer

Recent research published in The Journal of Nuclear Medicine reveals a promising targeted radiopharmaceutical therapy that may offer new hope for patients battling pancreatic ductal adenocarcinoma (PDAC). This innovative treatment, which demonstrated a potential for complete remission in preclinical models, specifically targets a protein expressed by certain pancreatic cancer cells. The study underscores the potential of this approach in addressing one of the most challenging and lethal forms of cancer.

PDAC is responsible for more than 90% of pancreatic cancer cases and has a notoriously grim prognosis, with a five-year survival rate of less than 5% in cases with metastasis. Currently, surgery offers the only potential cure but is applicable in just 10-20% of patients with localized tumors.

The study, led by Marika Nestor, a professor at Uppsala University in Sweden, investigated the efficacy of 177Lu-AKIR001, a novel radiopharmaceutical that specifically targets the CD44v6 protein found in some PDAC tumors. The treatment's role as both a standalone therapy and in combination with standard chemotherapy was assessed.

Through preclinical experiments, CD44v6 expression and the ability of 177Lu-AKIR001 to bind to the radioligand were evaluated across four PDAC cell lines. In mouse models bearing human PDAC xenografts, significant tumor uptake of 177Lu-AKIR001 was observed, with activity-dependent inhibition of tumor growth. Complete remission was achieved in 40% of cases administered 12 MBq of 177Lu-AKIR001 and in 14% of cases where the radiopharmaceutical was combined with paclitaxel chemotherapy. Importantly, the treatment was well-tolerated with no significant toxicity observed.

Professor Nestor noted the transformative role of targeted radiotherapies in treating prostate and neuroendocrine tumors and posited that CD44v6 could become a valuable target for such approaches in pancreatic cancer. The research contributes to expanding the clinical evaluation of 177Lu-AKIR001, currently being studied for various malignancies, with the aim to broaden patient inclusion in future clinical trials.

The authors of the study include Amanda Gustafsson, Hedvig Svedberg, and others from the Department of Immunology, Genetics and Pathology at Uppsala University. Their findings may pave the way for new, more effective treatments for patients with PDAC, addressing a critical need in oncology.

For more details, visit the Journal of Nuclear Medicine website.